HemostOD manufactures platelets on-demand from engineered stem cells.
Hemostod has raised $5.4M in total funding. The most recent round was Seed. The last funding was announced in October 2025.
Hemostod's investors include Polytech Ventures, Foundation for Innovation and Technology (FIT), Lichtsteiner Foundation, Orenok Holdings.
Hemostod is headquartered in Lausanne, Switzerland.
HemostOD manufactures platelets on-demand from engineered stem cells.
Hemostod is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Hemostod — Funding & Investors." VCBacked, October 1, 2025, https://www.vcbacked.co/company/hemostod. Accessed October 11, 2026.
VCBacked. (2025). Hemostod — Funding & Investors. Retrieved October 11, 2026, from https://www.vcbacked.co/company/hemostod
{{cite web |title=Hemostod — Funding & Investors |url=https://www.vcbacked.co/company/hemostod |website=VCBacked |access-date=October 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated